Ventripoint Diagnostics Ltd. announced today that its strategic partner, Lishman Global Inc., has formally submitted the VMS+™ 4.0 system to China’s National Medical Products Administration (NMPA) for regulatory approval. The submission has qualified for the NMPA’s “green channel” pathway, an expedited review process designed for innovative medical technologies addressing significant clinical needs. This designation is expected to streamline the regulatory timeline and facilitate faster market access.
China represents a substantial opportunity in cardiology, as cardiovascular disease remains the leading cause of mortality, affecting an estimated 330 million patients. Echocardiography is the most widely used cardiac imaging modality due to its cost-effectiveness and scalability, but variability in interpretation and limited access to advanced modalities like MRI have created demand for AI-driven tools. Ventripoint’s VMS+™ 4.0 provides MRI-equivalent volumetric measurements using standard 2D echocardiography, powered by the company’s proprietary Knowledge Based Reconstruction technology. The platform enables assessment of all four heart chambers, supporting diagnosis and management of congenital heart defects, heart failure, pulmonary hypertension, cardiotoxicity, and valvular disease.
“We are excited to take this important step toward bringing VMS+™ 4.0 to the Chinese market,” said Paul Gibson, Chief Technology Officer of Lishman Global Inc. “Qualification for the NMPA’s green channel underscores the clinical relevance and innovation of VMS+™ 4.0 and provides a clear pathway to accelerated adoption.” Hugh MacNaught, President and CEO of Ventripoint Diagnostics, added, “China is one of the most important cardiac care markets in the world. With the benefit of an expedited review pathway, we are well positioned to bring VMS+™ 4.0 to clinicians and patients more quickly.”
The VMS+ system is designed to work with all ultrasound systems from any vendor and has regulatory approvals in the U.S., Europe, and Canada. The company will provide further updates as the regulatory review progresses. For more information about Ventripoint, visit www.ventripoint.com.
Forward-looking statements in this release are based on expectations and assumptions, and actual results may differ materially due to risks detailed in the company’s filings on SEDAR at www.sedar.com.
